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Introduction
Melanin-concentrating hormone (MCH) was originally discovered as a 17 amino acid peptide hormone mediating the lightening of fish skin color (Kawauchi et al., 1983 ).
Subsequently, MCH was subsequently identified in the mammalian hypothalamus as a 19 amino acid cyclic peptide (Vaughan et al., 1989) . In the brain, cell bodies containing MCH are found exclusively in the lateral hypothalamus and zona incerta with projections to the dorsal and ventral striatum, prefrontal cortex, nucleus of the solitary tract and the parabrachial nucleus (Bittencourt et al., 1992; Skofitsch et al., 1985) . Immunoreactive fibers containing MCH are localized in subregions of the hypothalamus that are important for feeding and endocrine regulation and the limbic system where MCH is thought to regulate mood-related behaviors. Central administration of MCH increases food consumption by rodents (Qu et al., 1996) and chronic administration increased weight gain and susceptibility to diet-induced obesity (Gomori et al., 2003) . Genetic overexpression of MCH in mice produces obesity and insulin resistance (Ludwig et al., 2001 ) while MCH gene deletion results in resistance to weight gain on a palatable diet (Kokkotou et al., 2005) . Aged MCH-/-mice are resistant to the aging-related weight gain and weigh 25-30% less than control mice (Jeon et al., 2006) . MCH produces its effects through two G protein coupled receptors, MCHR1 and MCHR2 (for review see ). While MCHR2 is expressed in humans with a similar distribution pattern as compared to MCHR1 Hill et al., 2001; Sailer et al., 2001) , a functional MCHR2 is not expressed in rats and mice and so little is known about its physiological function. The highest densities of MCHR1 are found in the nucleus accumbens and caudate-putamen of rats and mice (Hervieu et al., JPET #143362 5 2000; Saito et al., 2001; Saito et al., 2000) . MCHR1 is localized to other brain regions implicated in the etiology of mood disorders including the locus ceruleus, amygdala and hippocampus (Hervieu et al., 2000) . MCHR1-/-mice are lean when compared to MCHR1+/+ controls but exhibit increased locomotor activity and hyperphagia (Chen et al., 2002; Marsh et al., 2002; Smith et al., 2008; Smith et al., 2005; Zhou et al., 2005) .
MCHR1 antagonism decreases feeding and adiposity indicating the importance in regulating body weight and composition (for review see (Kowalski and Sasikumar, 2007) ). While some work has identified mood-related phenotypes in the MCHR1-/-mice (Roy et al., 2007; Roy et al., 2006; Smith et al., 2006) , the pronounced increase in locomotor activity observed in these mice made those evaluations challenging.
Therefore, exploration of the effects of MCHR1 antagonism may provide more reliable and consistent data.
An emerging body of literature supports a role for MCH and MCHR1 in the endocrine and behavioral responses to stress. Central injection of MCH activates the endocrine stress response as evidenced by elevated plasma levels of adrenocorticotropic hormone (ACTH) and corticosterone (Kennedy et al., 2003; Smith et al., 2006) . In a number of stress-based animal models, several investigators reported that central administration of MCH produces anxiolytic-like effects in the elevated plus maze, open field and Vogel tests (Kela et al., 2003; Monzon and De Barioglio, 1999) . However, effects of MCH in the elevated plus test have ranged from anxiogenic (Smith et al., 2006) to no effect (Duncan et al., 2005) . MCHR1 gene deletion results in anxiolytic-like and antidepressant-like phenotypes (Roy et al., 2006; Smith et al., 2006) . When normal mice are subjected to a chronic mild stress paradigm, MCHR1 expression in the hippocampus This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on January 30, 2009 as DOI: 10.1124 at ASPET Journals on July 21, 2017 jpet.aspetjournals.org Downloaded from JPET #143362 6 is upregulated (Roy et al., 2007) and this is reversed by fluoxetine administration. In addition, MCHR1 antagonists produce anxiolytic-like actions in the social interaction test, elevated plus maze, stress-induced hyperthermia, and guinea pig maternal separation (Borowsky et al., 2002; Chaki et al., 2005; Smith et al., 2006) . Antidepressant-like behaviors were reported with MCH antagonism (Borowsky et al., 2002) and this antidepressant action may differ from the monoamine reuptake inhibitors in that it does not require neurogenesis (David et al., 2007) .
The aggregate weakness of the current literature is that a variety of MCHR1 antagonists were evaluated in different models with different routes of administration.
MCHR1 occupancy by the antagonists was not established in those studies to verify MCHR1 blockade in vivo and MCHR1-/-mice were not used to verify target mediated activity of the compounds. In the present study, we establish effective doses of the potent and selective MCHR1 antagonist, GW803430 (Hertzog et al., 2006) , in vivo and evaluated its activity in models predictive of anti-obesity and antidepressant efficacy.
We also establish that these activities are dependent on MCHR1 using MCHR1-/-mice. Quantitation was facilitated using the MCID Elite (St. Catherines, ON) image analysis.
Curve fitting and ED 50 determinations were accomplished using Graphpad Prism software (San Diego, CA).
Rat Feeding. Diet-induced obese (DIO) Long Evans male rats (Harlan Sprague
Dawley, Indianapolis, IN (starting average body weight was 535.6 ± 6.7 g) were acclimated (single housed) for at least 2 weeks in a temperature-(25°C) and lightcontrolled (12-h light, 12-h dark; lights on at 2200 h) environment. The animals were housed individually throughout the study and permitted to eat high fat/high sucrose palatable diet (TD 95217; Teklad) and drink ad libitum throughout the study. Rats were randomized to four groups and each group was comprised of five animals. Rats were treated daily by oral gavage with vehicle (saline, 1 ml/kg), 0.1, 1, or 3 mg/kg of GW803430. Body weight and food intake were measured daily at 0900 h. All data are shown as the mean ± SEM, and multiple group statistical comparisons were made using ANOVA repeated measures followed by Dunnett's test, using Graphpad Prism software.
Feeding in MCHR1+/+ and MCHR1-/-Mice. Adult, male MCHR1-/-and MCHR1+/+ mice were derived by heterozygous intercross and had a mixed 129SvJ x This article has not been copyedited and formatted. The final version may differ from this version. light : dark cycle (lights on 22:00h -10:00h) and individually housed throughout the study at ambient temperature. All mice had free access to water and a high fat/high sucrose diet (TD95217, Harlan Teklad, Madison, WI). After 2 weeks acclimation to the facility, naïve mice were treated by oral gavage at 1 hour prior to onset of dark period with vehicle or 3 mg/kg GW803430 for 4 days. Body weight of the mice and weight of food consumed in the last 24 hours were measured daily. Statistical Analyses were performed by two-way ANOVA followed by Tukey's t-test.
Sweetened-Condensed Milk Consumption in MCHR1+/+ and MCHR1-/-mice.
Animals were maintained on a 12 hr light/dark cycle (lights on 22:00h -10:00h) and individually housed throughout the study at ambient temperature. All mice had free access to water and a high fat/high sucrose diet (TD95217, Harlan Takled, Madison, WI). After 2 weeks acclimation to the facility, naïve mice were given 1:2 diluted sweetened-condensed milk for 2 hours at onset of dark period. On day 4, 2 hours before presentation of sweetenedcondensed milk, mice were treated by oral gavage at 1 hour prior to onset of dark period with vehicle or 10 mg/kg GW803430. Sweetened-condensed milk consumed each day was measured. Statistical Analyses were performed by one-way ANOVA followed by experiments. This mouse strain was used in this assay since they are the standard strain for which our lab has optimized the assay (Bai et al., 2001) . In one experiment, MCHR1-/-mice and their littermate MCHR1 +/+ controls were used (see description of mice above). This experiment was carried out to ascertain whether the antidepressant-like effects of GW803430 would be absent in mice without MCHR1. Mice were maintained on a 12hr light/dark cycle (0600/1800 hours), and all procedures were performed between 12:00 PM and 4:00 PM. Animals were removed from the vivarium to the testing area in their home cages and allowed to adapt to the new environment for at least 1 h before testing. The forced swim test was performed using the original method described by Porsolt et al. (Porsolt et al., 1977) . In brief, mice were placed individually in clear plastic cylinders (10 cm in diameter by 25 cm in height) filled to 6 cm with 22-25°C water for 6 min. The duration of immobility was recorded during the last 4 minutes of a 6-minute trial. A mouse was regarded as immobile when floating motionless or making only those movements necessary to keep its head above the water. Dose-effect functions for GW803430 were carried out by dosing mice p.o., 4 hrs prior to testing. Imipramine was used as a comparator standard (15 mg/kg, p.o., 30 min prior). Statistical Analyses were performed by ANOVA followed by Dunnett's test.
Tail-Suspension Test. This assay detects the activity of antidepressants and is used here as a modification of the procedure of Steru et al., 1985 (Steru et al., 1985 .
Male, C57BL/6 mice (Jackson Labs) weighing about 25 g were suspended by their tails from the edge of a shelf 80 cm above the floor. This mouse strain was used since it has been the most well characterized under these assay conditions (Bai et al., 2001 ).
Immobility, defined as the mice hanging passively without movements to right (Malatynska et al., 2002) , experimentallynaïve male Sprague-Dawley rats, weighing 160-180 grams at the start of the study, all procedures were performed between 12:00 PM and 4:00 PM in ambient room light.
The testing apparatus was constructed from transparent plastic material and consisted of two identical chambers (24 x 17 x 14 cm) connected by a round tunnel (4.5 cm diameter x 52 cm long). A container (10 ml beaker) of sweetened milk (9 % sucrose) was placed in an opening in the floor at the mid-point of the tunnel. Animals were food deprived over-night prior to the first test session. During the testing period, each member of a pair was placed in the different chambers of the testing apparatus, the gates were opened, and the time spent drinking was recorded for each animal for a 5 minute period. At the end of the 5-minute testing period, animals were returned to their home cage and given free access to food for 1 hour. The animals were also given free access to food from Friday afternoon (following the test session) to Sunday morning, when they were once again food-deprived. During the first week of the testing (acclimation week), drinking time was not scored. During the second week of testing (selection week), the time spent drinking was recorded. Pairs of animals that passed the following criteria continued into the drug administration phase of the experiment: (1) the difference between the average daily drinking scores of the two animals was significant (two-tailed t-test, p < 0.05); and, (2) the dominant animal's score was at least 25% greater than the submissive animal's score.
Any pairs not passing the selection criteria were dropped from the study. The animal of a pair with the higher drinking score was labeled as "dominant" and the animal of a pair with lower drinking score was labeled as "submissive". The submissive rat of each pair was treated with the test compound while the dominant rat of each pair was treated with vehicle for the next 21 days. The 5-minute test was repeated once daily, except weekends, for 21 days following the beginning of the drug treatment. Dominance levels This article has not been copyedited and formatted. The final version may differ from this version. Marble-burying and rotorod performance. Marble-burying behavior in mice has been reported to be inhibited by anxiolytics and is one of the only assays that might detect anxiolytic activity of antidepressant agents after acute dosing (Borsini et al., 2002) .
We used the method described by Li et al. (Li et al., 2006) which utilized male, NIH Swiss mice (as described above in mouse forced swim methods). In these experiments, 20 marbles were placed atop 5 mm sawdust bedding within a plastic tank. After 30 min, the number of marbles buried was counted (2/3 buried by sawdust). Prior to this test, mice were placed on a rotating rod (6 rotations/min) and rotorod failures were defined if a mouse fell off the rod on two occasions within a two min test period. No pretraining on either test was performed. Dose-effect functions for GW803430 were carried out by dosing mice p.o., 4 hrs prior to testing. Chlordiazepoxide HCl (i.p, 30 min prior) was used as a comparator standard. The highest dose of 30 mg/kg was used as this is the minimal effective dose in the marble-burying assay (Li et al., 2006) and the mouse Vogel conflict test with food (Witkin et al., 2004) . Effects of drugs on marble-burying were assessed by ANOVA followed by Dunnett's test. Drug effects on rotorod performance were evaluated by Fisher's exact probability test.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Establishing effective doses of GW803430 using rat ex vivo autoradiography.
Initial studies were performed to establish doses of GW803430 that effectively inhibited binding to the MCHR1 receptor. To accomplish this, animals were administered the compound by the oral route and sacrificed 4 hours after administration.
The brains from the animals were subjected to ex vivo autoradiography to assess how effectively the compound concentrations within the brain tissue inhibited the binding of 125 I-S036057 to the MCHR1 receptor. In these studies, the binding to three brain regions was assessed using image analysis techniques. The ED 50 for these brain regions ranged from 0.05 to 0.56 mg/kg ( Figure 1 ). Based on these results, doses of 1 mg/kg or greater would be expected to effectively antagonize a majority of the rat brain MCHR1 receptors in vivo.
Effect of GW803430 on food intake and body weight.
Having established the effective doses of GW803430, we evaluated whether the doses capable of inhibiting binding ex vivo were capable of affecting food consumption and body weight in diet-induced obese (DIO) rats. In these studies, rats were administered the compound for 14 days during which food consumption and body weight were monitored. Compared to vehicle controls, there was a decrease in body weight at 0.1 mg/kg but this did not reach significance ( In a subsequent study, the effects of MCHR1 antagonism on sweetenedcondensed milk consumption was evaluated using MCHR1+/+ and MCHR1-/-mice. In these studies the mice were allowed access to sweetened-condensed milk for one hour a day. During the first three days, a stable baseline was established and on the fourth day, the animals were treated with 10 mg/kg GW803430. During all four days of evaluation, 
Effects of GW803430 in the mouse forced swim test
To understand the potential role of MCHR1 antagonism in models used to predict antidepressant effects, we evaluated the effects of GW803430 in the mouse forced-swim test. In these studies, we evaluated the effects of the compound after acute and subchronic administration. With acute administration, GW803430 produced a dosedependent reduction in immobility time that was statistically significant at 3 mg/kg (F 4,34 = 4.91, p < 0.005) ( Figure 5A ). When administered for five consecutive days, GW803430 produced a dose-dependent reduction in the immobility time with the 3 and 10 mg/kg doses reaching statistical significance (F 3,31 = 4.74, p < 0.005) ( Figure 5B ).
To better define the mechanism of action of this antidepressant-like effect of GW803430, compound was studied under the forced-swim test in both MCHR1+/+ and in MCHR1-/-mice. Although GW803430 (10 mg/kg) decreased immobility in MCHR1+/+ mice, this effect was absent in MCHR1-/-mice ( Figure 6A ). ANOVA revealed a significant genotype by drug condition interaction (F 1,26 = 90.9, p < 0.005), and non-significant overall effects of drug treatment (F 1,26 = 0.72) and of genotype (F 1,26 = 0.22).
Imipramine significantly decreased immobility in both MCHR1+/+ and MCHR1-/-mice (F 1,27 = 68.8, p < 0.0001), There were no significant differences between strains (F 1,27 = 3.1, p = 0.57) and no drug x strain interactions (F 1,27 = 0.33, p = 0.09) ( Figure 6B ). The effects of GW803430 in the mouse tail suspension and rat dominance assays.
To extend the generality of the findings on GW803430 in the forced-swim test, GW803430 was also evaluated in the mouse tail-suspension test. GW803430 decreased immobility in this assay with a minimal effective dose of 10 mg/kg (F 4,38 = 7.02, p < 0.001) (Figure 8 ). To further substantiate the antidepressant-like effects of MCHR1
antagonism, we evaluated the effects of GW803430 in the social dominance test. This paradigm is important in that 1) it detects actions of antidepressant agents after subchronic but not after acute dosing and 2) because it is believed to reflect the delayed onset of antidepressant action. In this study, a 30 mg/kg dose was administered for three weeks and the animals were assessed prior to treatment and at one week intervals for three weeks during treatment. In this study, GW803430 produced a reduction in submissive behavior ( Figure 9A ; F 3,14 =4.71, p=0.018) that reached statistical significance (p<0.05) 2 and 3 weeks after treatment. These data are consistent with our previous unpublished findings with significant antidepressant-effects of fluoxetine and of imipramine (both studied at 10 mg/kg/day) that was detected at 3 weeks post dosing. In this study, body weight was also evaluated and a statistically significant reduction (p<0.05) was observed 14, 21 and 25 days after treatment ( Figure 9B ).
Effects of GW803430 in the mouse marble burying assay.
Marble-burying of mice was also studied as a method for assessing the potential anxiolytic-effects of GW803430. GW803430 dose-dependently decreased marbleburying of mice with a dose as low as 3 mg/kg being effective ( 
Discussion
In the present study, we have evaluated the effects of the specific MCHR1
antagonist, GW803430 on feeding and body weight in rats. Using ex vivo autoradiography, we established that this antagonist inhibits MCHR1 binding in three areas of the brain and exhibits substantial occupancy of the MCHR1 in these brain regions at doses of 1 mg/kg and greater. In subsequent studies using diet-induced obese (DIO) rats, 14-day administration of the MCHR1 antagonist produced a robust and dosedependent decrease in food intake and body weight. These results are consistent with previous results reported with this compound using DIO AKR/J mice (Hertzog et al., 2006) . Given that treatments can reduce feeding and body weight through off target mechanisms, we evaluated the effects of 10 mg/kg GW803430 in MCHR1+/+ and MCHR1-/-mice for four days. Using this paradigm, the compound should be effective in the MCHR1+/+ but not the MCHR1-/-mice if the compound is producing its effects via administration of an MCHR1 antagonist reduced feeding, reduced body weight and improved hypercholesterolemia, hyperinsulinemia and hyperglycemia in DIO mice (Mashiko et al., 2005) . A number of nonpeptide MCHR1 antagonists produce weight loss in preclinical models (for reviews see (Kowalski and Sasikumar, 2007; Luthin, 2007) ). Combined with the present data, these data add to the growing literature linking MCH receptor mechanisms to the regulation of food intake and body weight.
In a subsequent study, the ability of GW803430 to inhibit sweetened-condensed milk consumption was evaluated. This model was used to evaluate the effects of the compound on highly palatable food consumption prior to conducting the submissive behavior model that relies on sweetened milk consumption to assess dominant and subordinate relationships. During the baseline evaluation, there was a modest difference between the MCHR1+/+ and MCHR1-/-mice with the knockouts exhibiting reduced consumption. These results are surprising since the MCHR1-/-animals are reported to be hyperphagic (Chen et al., 2002) . Interestingly, GW803430 had no effect on the consumption of sweetened condensed milk when administered prior to the feeding session on the fourth day in either mouse line when compared to vehicle controls. Based on these results, it would not be anticipated that MCHR1 receptors participate in rewardbased or palatable food consumption in mice. These results also decrease the likelihood that direct effects of the compound on sweetened milk consumption would be a (Smith et al., 2005) , but this was not observed when animals were treated with GW803430 for up to three weeks (data not shown). Therefore, it is likely that both the hyperphagia and increased metabolism are are a consequence of the increased locomotor activity seen in the MCHR1-/-mice, but not seen with MCHR1 antagonism.
Having established effective doses of GW803430 using both an occupancy measure and a pharmacodynamic response (feeding in the diet-induced obese rat), we assessed the ability of this compound to affect behavioral and biochemical measures in rat and mouse mood disorder models. To evaluate the potential of MCHR1 antagonism in the treatment of depression, we used the forced swim test, a validated model of antidepressant action (Porsolt et al., 1977) . In the mouse forced swim test, GW803430 To further expand on the observed antidepressant-like activity of the MCHR1 antagonist in the mouse models, we utilized a dominance/submissive paradigm that has previously been used to model the delayed antidepressant onset of monoamine reuptake inhibitors (Malatynska et al., 2002) . In this model, animal pairs were selected based on dominant and subordinate relationships. Once these relationships have been established, they will continue in a quantitative manner for at least seven weeks (Malatynska et al., 2007) . Test compounds were administered daily to subordinate animals for three weeks.
During the period of compound administration, the subordinate animals exhibited JPET #143362 23 increased sweetened milk consumption (feeding time) consistent with an antidepressantlike action. In addition, it is important to note that we saw no effect of acute compound treatment on sweetened-condensed milk consumption in mice indicating that effects on milk consumption per se should not be a confounding variable in the dominance assay.
Interestingly, the antidepressant-like effect in this assay became apparent at one week and statistically significant at two weeks indicating MCHR1 antagonists may have a more rapid onset of action than conventional agents. These findings contrast with data on the First-line therapies for mood disorders also have anxioltyic effects (e.g., selective serotonin uptake inhibitors). Engaging both antidepressant along with anxiolytic effects should therefore be a desirable feature of a new antidepressant. Indeed, a host of data has accumulated that supports the anti-anxiety-like effects of MCHR1 antagonism (Borowsky et al., 2002; Chaki et al., 2005; David et al., 2007; Smith et al., 2008) . We used marble-burying to assess potential anxioltyic-like effects of the MCHR1 antagonists GW803430 (Borsini et al., 2002; Li et al., 2006) . In this assay, GW803430 potently decreased marble-burying at doses without any effect on motor behavior measured on the rotorod. The benzodiazepine anxiolytic chlordiazepoxide also decreased marble-burying but only did so at a dose (30 mg/kg) that is effective in other anxiolyic tests in mice (Witkin et al., 2004) and at doses that produce motor impairing effects (see also Li et al.,
2006).
In a recent study, David and coworkers (David et al., 2007) This article has not been copyedited and formatted. The final version may differ from this version.
